Lab tests aim to tailor cancer treatments for patients who've run out of options
NCT ID NCT06024603
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests whether doctors can quickly recommend personalized cancer treatments for adults whose cancers have returned or stopped responding to standard therapy. Researchers will take a sample of the tumor, test it against many drugs in the lab, and also analyze its genes. The goal is to see if they can provide a ranked list of treatment options within 4 weeks for at least 22 out of 36 participants. This approach could help match patients to drugs that might work better for their specific cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Drug Sensitivity Test (DST) and genomic profiling
- What this could lead to
- If successful, this could pave the way for personalized cancer treatments tailored to each patient's tumor, potentially improving outcomes for those with limited options.
- What could go wrong
- This is a small, early feasibility study (36 participants) focused on whether recommendations can be made in time, not on effectiveness. The approach may not work for all cancer types or may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Florida International University
Miami, Florida, 33199, United States
-
Lerner College of Medicine, Cleveland Clinic Florida
Weston, Florida, 33331, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug shows promise for stubborn cancers
- New drug combo aims to tackle recurrent brain lymphomas
- New hope for kids with resistant tumors: drug combo enters safety trial
- New hope for recurrent glioblastoma: experimental drug LMP744 enters human trials
- New Three-Drug cocktail aims to outsmart tough leukemia